aintenance of sinus rhythm (SR) is the goal in patients with paroxysmal atrial fibrillation (AF). Aprindine, a class I antiarrhythmic drug, was approved for the treatment of ventricular and supraventricular tachyarrhythmias in 1987 in Japan, but its preventive effect on the recurrence of paroxysmal AF has never been tested. Digoxin is also commonly prescribed in patients with paroxysmal AF to prevent the paroxysms and to control the ventricular response during the episode, 1 but to date there is no evidence that it is helpful in achieving either of these therapeutic goals. There is only one reported double-blind, placebo-controlled trial of digoxin 2 and the effect of digoxin for this purpose was estimated as small. The median times to the first and second episodes were compared and it was found that although digoxin lengthened the event-free interval significantly there was no significant difference shown by log-rank test. a class I antiarrhythmic drug has never been compared with digoxin in a double-blind, parallel design trial, so we conducted a multicenter, placebo-controlled, randomized, double-blind trial to test the preventive effect of aprindine and digoxin on the recurrence of AF in comparison with placebo, and also to compare the effectiveness of these 2 drugs in the prevention of AF.
a class I antiarrhythmic drug has never been compared with digoxin in a double-blind, parallel design trial, so we conducted a multicenter, placebo-controlled, randomized, double-blind trial to test the preventive effect of aprindine and digoxin on the recurrence of AF in comparison with placebo, and also to compare the effectiveness of these 2 drugs in the prevention of AF.
Methods
The protocol of our prospective randomized, doubleblind, placebo-controlled, parallel group multicenter study comparing the effectiveness of aprindine and digoxin with that of placebo in maintaining SR in patients with paroxysmal AF or cardioverted persistent AF was approved by the Institutional Review Board at each of the 36 participating centers. Written informed consent was obtained from each patient. Patients were eligible if they had a history of documented symptomatic paroxysmal AF with a frequency of at least monthly and no more than 2 episodes per week, or if they had the persistent form of AF that had lasted for less than 1 month. In the case of persistent AF, SR had to be successfully restored either by direct current or by therapy with class I antiarrhythmic drugs. Whether a patient underwent cardioversion or not, and whether DC or a class I antiarrhythmic drug was used, was left to the discretion of the attending physician. Adequate anticoagulation therapy starting at least 3 weeks before and continuing for 1 month after cardioversion was strongly recommended.
Exclusion criteria included inability to tolerate withdrawal from current antiarrhythmic therapy, myocardial Circ J 2002; 66: 553 -556 (Received September 20, 2001; revised manuscript received February 21, 2002; accepted February 27, 2002 Aprindine capsules containing 20 mg of aprindine hydrochloride, digoxin tablets containing 0.25 mg of digoxin, and matching placebo capsules and tablets identical in size, weight, color and taste were manufactured, packed, labeled and distributed by the sponsor of the study (Mitsui Pharmaceutical Inc, Tokyo, Japan).
After cardioversion in patients with persistent AF or during SR in those with paroxysmal AF, patients were randomized to one of the 3 treatment groups by a computer-generated randomization list common to all centers. To avoid extra-cardiac adverse effects in aged patients, we chose 40 mg of aprindine as the daily dose. All patients received 2 capsules and 1 tablet: in the aprindine group, two 20 mg aprindine capsules and a placebo tablet, in the digoxin group, 2 placebo capsules and a 0.25 mg digoxin tablet, and in the placebo group, 2 placebo capsules and a placebo tablet.
Compliance with the medication was checked by the patients' physicians, who saw them on an out-patient basis every 2 weeks for 6 months. At each visit, a resting 12-lead electrocardiogram (ECG) was recorded. The primary endpoint of the study was relapse of AF occurring during the 6-month follow-up. Such a recurrence was defined as AF lasting at least 1 min as documented by ECG or an obvious subjective symptom suggesting a recurrence of AF later confirmed by ECG.
Statistical Analysis
Summary data are expressed as mean ± SD or numbers and percentages of patients. Analyses were performed according to the intention-to-treat principle, and we used chisquare tests to compare proportions of patient characteristics at baseline. For all comparisons, statistical significance was assessed at the 0.05 level using 2-tailed p values. The power calculation for the primary end point, namely relapse of AF, indicated that 50 patients per group were needed. This power calculation (80% power, =0.05, 2-sided) was made on the assumption that 80% of patients in the placebo group would undergo a relapse over the 6-month follow-up period and that aprindine would decrease this number to 60%. The cumulative risk of recurrence of AF was estimated by the Kaplan-Meier method, and the difference between treatment groups was assessed with the log-lank test. A correction adjustment was performed for other variables examined by the likelihood-ratio test using the proportional-hazards model (Cox regression model). Data on heart rate were compared using the t-test, and descriptive statistics were given for other variables.
Results
A total of 144 patients with AF were enrolled: 85 (59%) had paroxysmal AF and the remaining 59 (41%) had converted persistent AF. Randomization was done during SR. One patient with paroxysmal atrioventricular reentrant tachycardia failed to meet the entry criteria, and another 2 patients (no follow-up information available for personal reasons) were withdrawn from analysis. Therefore, 47 patients were assigned to the aprindine group, 47 to the digoxin group, and 47 to the placebo group.
Baseline Characteristics of the Patients (Table 1)
With the exception of the percentage of patients aged more than 65 years, there were no significant differences between the groups.
Recurrence of AF
Over the course of a mean follow-up period of 183±18 days, the intention-to-treat analysis showed that 36 patients (77%) in the placebo group, 32 (68%) in the digoxin group and 30 (64%) in the aprindine group had a relapse of AF (p=0.543). Fig 1 shows the actuarial probability of remaining in SR without a recurrence of AF for the 3 treatment groups (33% on aprindine, 28% on digoxin and 26% on placebo). The median time to relapse of AF was 21 days in the digoxin group, 23 days in the placebo group and 36 days in the aprindine group, but these differences were not statistically significant. In patients with paroxysmal AF, the median time, measured as starting during SR, to the relapse of AF was significantly longer in the aprindine group (38 days; p<0.05) than in the digoxin group (11 days), but not significantly so in the placebo group (14 days).
To take into account the pharmacokinetics of digoxin and previously prescribed drugs prior to entry into this trial, we re-analyzed the patients remaining in SR for 15 days from the start of the trial (30 patients on aprindine, 26 on digoxin, and 27 on placebo). There was also no significant inter-group difference, but there were significantly higher proportions of patients free from recurrence in the aprindine group (56.7%) than in the placebo group (40.7%; Cox proportional-hazards model: p=0.0414) when adjustment for age distribution was made. But there were no significant differences between aprindine and digoxin (p=0.734) or digoxin and placebo (p=0.206). Fig 2 shows the probability of remaining in SR without recurrence of AF in the 3 groups: there were higher rates for aprindine than for placebo in all subgroups analyzed. However, because the small number of patients was not sufficient for analysis of the subgroups, only descriptive statistics for this comparison are given in Table 2 .
Safety and Tolerability of Treatment
The number of patients included in the safety analysis was not the same as that included in the efficacy analysis. The safety analysis involved a total of 144 patients, which was all the patients who had received at least 1 dose of the study drug and for whom post dose data were available. Two patients assigned to the aprindine group (one with exanthema, the other with elevation of aspartate aminotransferase and alanine aminotransferase), 4 patients assigned to the digoxin group (3 with epigastric discomfort and 1 with elevation of aspartate aminotransferase and alanine aminotransferase), and 3 assigned to the placebo group (1 with urticaria, and 2 with elevation of aspartate aminotransferase and alanine aminotransferase) were withdrawn from the study. They all recovered without receiving any treatment for their adverse events. There was no difference in the frequencies of withdrawn patients among the groups.
Discussion
This multicenter double-blind study is the first clinical trial comparing a class I antiarrhythmic drug and digoxin with placebo. It shows that the proportion of patients remaining in SR over the study period of 6 months was higher on aprindine than on digoxin or placebo, and in patients remaining in SR for 15 days from the start of this trial, there was significantly higher proportion of patients remaining free from AF recurrence on aprindine than on placebo.
Aprindine is a class I antiarrhythmic drug with clinical effects on various supraventricular arrhythmias. [3] [4] [5] Its reported electrophysiologic effects on the human atrium 6 for the suppression of the development of AF have been favorable, but its preventive effect on the recurrence of AF has not been reported. Since Anderson et al reported the preventive effects of flecainide on the recurrence of paroxysmal AF in a study using a transtelephonic monitoring system, 7 there have been many reports of trials related to AF prevention with antiarrhythmic drug. Roy et al recently reported a far higher rate of nonrecurrence in patients with paroxysmal AF receiving amiodarone treatment than among those with similar recurrence rates to the patients given Estimates after adjustment of the age distribution of the proportions of aprindine-and placebo-group patients with no recurrence of atrial fibrillation (AF) and who remained in sinus rhythm (SR) 15 days after randomization. A significantly higher proportion remained recurrence-free on aprindine than on placebo (Cox proportional-hazards model: p=0.0414). flecainide who were given sotalol or propafenone. 8 The rate of recurrence for paroxysmal AF is usually higher than for cardioverted persistent AF, but in the present study, which included both types of AF, there was no clear difference, probably because of the small number of patients. The proportions of the patients who were still in SR at the end of the follow-up were 33% on aprindine, 28% on digoxin and 26% on placebo, and the ratio on aprindine is comparable to that with other antiarrhythmic drugs evaluated with transtelephonic monitoring. 7, 8 In general, AF may become asymptomatic after antiarrhythmic or digoxin treatment and therefore the ratio of the patients remaining in SR may increase. In the present study, even with the low dose of the study medications, more than 30% of patients on aprindine and 26% on digoxin were still in SR at the end of the follow-up period. The preventive effect on the recurrence of paroxysmal AF by digoxin was 12.4% in a previous report, 2 which lower than our ratio and may be related to the type of AF included in the present study; however, it is difficult to deny that the relatively higher ratio of patients remaining in SR reflects an increase in the number of asymptomatic patients. In the present study, it was only with paroxysmal AF that the aprindine group had a significantly longer median time to relapse of AF than the digoxin group, but there was no difference in the placebo group. It is very interesting that, of the 3 groups, it was the digoxin group that revealed the shortest median time to AF relapse and this observation may be related to digoxin's vagotonic action on the atrial myocardium. Murgatroyd et al 2 estimated that the effect of digoxin is small compared with that of other antiarrhythmic drugs such as flecainide and they concluded that digoxin reduces the frequency of paroxysmal AF, but mainly through ventricular rate control and that its direct atrial antiarrhythmic action does not seem to contribute to its clinical effects on AF recurrence because of its direct electrophysiologic action on atrial muscle. Rawles et al reported that pretreatment with digoxin does not seem to reduce either the frequency of paroxysms or the ventricular rate when the paroxysms recurred and moreover, it was associated with longer attacks. 9 We also found that the effect of digoxin on AF recurrence was small, in concurrence with Murgatroyd et al. 2 
Study Limitations
The enrolled patients had less frequent structural heart disease than the general AF population and furthermore, we examined only a small number of patients. A transtelephonic monitoring system is strongly recommended, but we were not able to employ this system and so only recruited symptomatic patients. The study could also not evaluate the blood levels of the study medications to confirm any relationship with clinical effects.
Conclusions
Neither aprindine nor digoxin demonstrated a significant effect in preventing relapse of symptomatic AF; however; the recurrences occurred later with aprindine than with placebo or digoxin. Therefore, aprindine may reduce the recurrence of symptomatic AF.
